Abstract
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare, highly aggressive hematologic malignancy originating from plasmacytoid dendritic cell precursors. We present the case of a 58-year-old male with localized cutaneous nodules and no initial systemic involvement. Despite standard chemotherapy, the disease progressed rapidly, resulting in death within three months. This case emphasizes the diagnostic importance of specific immunophenotypic markers and the need for more effective therapeutic strategies.
Introduction
BPDCN often presents as skin lesions, such as nodules or plaques, which can lead to diagnostic delays. It is known for its aggressive clinical course and frequent systemic involvement. A major challenge is that patients may appear systemically stable at presentation, with normal blood counts and bone marrow, yet still harbor a disease that progresses with devastating speed.
Case Presentation and Diagnostic Methods
A 58-year-old Chinese male presented with a 3-month history of multiple purple nodules on his back and shoulder. Initial blood work and bone marrow examinations were normal, suggesting no extracutaneous manifestation at that time.
A skin biopsy was performed to establish a diagnosis. The diagnostic approach included:
- Gross Pathology: Assessment of the tumor's physical characteristics.
- Histopathology: H&E staining to observe cellular morphology and infiltration patterns.
- Immunohistochemistry (IHC): A panel of markers (CD4, CD56, CD123, CD43, CD3, CD5, CD20, CD30, granzyme B, and TdT) to differentiate BPDCN from other lymphomas.
- In Situ Hybridization: To rule out Epstein-Barr virus (EBV) infection.
Results
Gross examination of the skin mass showed a tan-white cut surface with a firm consistency and obscure boundaries. Histological examination revealed a dense and diffuse infiltrate of monomorphous medium-sized cells in the dermis and subcutis.
The diagnosis of BPDCN was confirmed by IHC findings: tumor cells were positive for CD4, CD56, CD123, and CD43. They were negative for T-cell (CD3, CD5), B-cell (CD20), and cytotoxic markers (granzyme B), as well as TdT. EBV testing was negative.
Clinical Course
The patient was treated with four courses of CHOP chemotherapy (cyclophosphamide, adriamycin, vincristine, and prednisone). Following treatment, he developed persistent high fever and pancytopenia. He died three months after his initial presentation, illustrating the rapid progression of the disease.
Discussion
This case highlights the "triple threat" diagnostic signature of BPDCN: positivity for CD4, CD56, and CD123. CD123 is particularly critical as a highly specific marker for this lineage.
The patient's initial "extracutaneous-negative" status was deceptive, as it did not correlate with a more indolent course. The failure of the CHOP regimen underscores the inadequacy of standard lymphoma treatments for BPDCN and supports the investigation of more intensive leukemia-like therapies or novel targeted agents, such as those directed at CD123.
Summary updated